US IPO Market Posts Its Slowest 2Q Since the Great RecessionJust 21 IPOs raised $2.1 billion in the US IPO market’s slowest second quarter since 2009....read more
Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum...read more
Belite Bio, a Phase 3 biotech developing an oral therapy for retinal degeneration diseases, raised $36 million by offering 6 million ADSs at $6, the midpoint of the range of $5.50 to $6.50. Parent Lin BioScience agreed to purchase $15 million worth of ADSs in...read more
Updated Monday, 4/25. The April IPO market is expected to close out with norovirus vaccine developer HilleVax (HLVX), along with two healthcare micro-caps. Other small deals and SPACs may join the calendar during the week. ...read more
Updated: Renaissance Capital's 2Q 2022 US IPO Market Review
US IPO Market Posts Its Slowest 2Q Since the Great Recession Just 21 IPOs raised $2.1 billion in the US IPO market’s slowest second quarter since 2009....read more
US IPO Weekly Recap: 4 IPOs price, led by norovirus biotech HilleVax
Four IPOs raised $266 million this week, headlined by norovirus vaccine developer HilleVax (HLVX). The other three deals were micro-caps, an area of the IPO market that continues to see rapid price swings thanks to interest from momentum...read more
Eye disease biotech Belite Bio prices US IPO at $6 midpoint
Belite Bio, a Phase 3 biotech developing an oral therapy for retinal degeneration diseases, raised $36 million by offering 6 million ADSs at $6, the midpoint of the range of $5.50 to $6.50. Parent Lin BioScience agreed to purchase $15 million worth of ADSs in...read more
US IPO Week Ahead: April closes out with 3 healthcare IPOs
Updated Monday, 4/25. The April IPO market is expected to close out with norovirus vaccine developer HilleVax (HLVX), along with two healthcare micro-caps. Other small deals and SPACs may join the calendar during the week. ...read more